TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lower Extremity Muscle Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Percentage of Type II (Fast-twitch) Muscle Fibers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Distance Monocular Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total DS3 severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of pelvic floor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pelvic floor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in QoL data during teduglutide therapy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Best response rate (CR + PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: variation of knee joint space thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: proportion of patients with pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Vital signs assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory variables assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECG assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MIQ-3 total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Subjects With an Anamnestic Response to the HBV Challenge Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sedation Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Serum Concentration of Inflammatory Biomarkers (Other Than TNF-alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Sputum Concentration of Inflammatory Biomarkers (Other Than IL-6 and G-CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Serum Concentration of Inflammatory Biomarkers (TNF-alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Sputum Concentration of Inflammatory Biomarkers (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Sputum Concentration of Inflammatory Biomarkers (G-CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cohen's kappa coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intra-procedural Hemorrhage Grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Consent and successful genotyping rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: [1-13C]lactate-to-H13CO3- ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: [2-13C]lactate-to-[5-13C]glutamate ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neurological Soft Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Psychopathology Symptoms Assessed by PANSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Rating of Subjective Symptoms of VKC in Period I
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Rating of Objective Symptoms of VKC in Period I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of complete remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of CR with incomplete blood count recovery (CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence rates of post-transplant lymphoproliferative disorder (PTLD)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in slough and necrotic tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount and quality of granulation tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood pressure during the nighttime sleep period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in sleep during the nighttime sleep period
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in insomnia severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Average flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Activated CD8+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Correlation between optical biopsy and anatomopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: failure ratio
Endpoint domain: Mortality/survival
Primary endpoint: withdrawal ratio
Endpoint domain: Adverse events/effects
Primary endpoint: Change in high-sensitivity C-reactive protein (hs-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Vessel enlargement in mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of serious adverse events device and procedure related
Endpoint domain: Adverse events/effects
Primary endpoint: Worry levels in children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Amount of Intraoperative RBC Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ability to use femoral artery closure device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: AF and SR classification accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in chromatin density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Inspiratory Pressure Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Self-Reported Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: successful radiographic bone repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency Counts and Percentage of Subjects With Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration Curve [AUC]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Cmax is Observed [Tmax]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Analyte Concentration (Cmax) of Drospirenone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0-last]) of Drospirenone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Drospirenone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Ethinylestradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Scale (QOLS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Detection of pneumothorax/pleural effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in NYHA Functional Class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in 6-Minute Walk Distance (6-MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visualization of late gadolinium enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients With Adverse Events (AEs) Grade ≥ 3
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Immune-mediated Adverse Events (imAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of n-6 HUFA in Total HUFA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with somatic and germline mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response Rate for the Individual Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission in Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung Injury Score (LIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: EuroQol-5D (EQ-5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cumulative rate of culture-confirmed or clinically diagnosed TB disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Tibial tubercle-trochlear groove (TT-TG) offset distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with pancreatic enzyme replacement therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Peak Plasma Concentration (Cmax) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Peak Concentration (Tmax) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Concentration-Time Curve Extrapolated to Infinite Time (AUC0-∞) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (t1/2) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy for detection of congenital heart defects (CHDs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression-free Survival (PFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Phase difference (PD) in degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI responses in components of reward circuits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safe doses of CEND-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal Biological Dose (OBD) of CEND-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastroparesis Cardinal Symptom Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Esophageal anastomosis leak requiring surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Retention in Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Achieving at Least a 20% Reduction From Baseline Hour 0 IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Cycle cancellation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduced blood flow in the retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in the blood flow to the retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite Endpoint of Total Venous Thromboembolic Event (VTE) and All Cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of skin lesion grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Induced Sputum Gene Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper airways obstruction levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Air quality measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of upper respiratory tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of EVs and HEVs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of Isradipine CR
Endpoint domain: Adverse events/effects
Primary endpoint: Measure of Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity assessed by the Haemagglutination (HI) Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Curve (AUC) of NRS-R Pain Intensity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Global Impression of Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Psychological Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Surgical approach outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: complete resection rate (R0 rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PASI75 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: ADHD Rating Scale (ADHD-RS) parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative prostate V100%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in numerical pain rating score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in disability score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in hemoglobin levels during ICU stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of transfusions during ICU stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Insulin-like growth factor-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin-like growth factor binding protein-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of smokers referred to tobacco cessation website
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: summed pain intensity difference over 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Effects After Genotype-guided PPI Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Metabolic variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: success of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of Antibiotic Therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Initiation of osteoporosis management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of coronary artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean keratometry value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric Rating Scale for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough forced expiratory volume in one second (FEV1) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Transition Dyspnoea Index (TDI) focal score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Step Width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step Asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Lesions Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in the extent and duration of sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in the extent and duration of motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in the heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in the non invasive mean arterial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cancellation or postponement of consultations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient cancellation of teleconsultations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cancellation or postponement of hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in modalities of administration of antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Systemic exposure of FF and UMEC and VI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma concentration-time curve from 0 to last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma concentration-time curve from 0 to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Skin Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of grade 3-5 hemoptysis
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Wound Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in moderate-to-vigorous physical activity (MVPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of people receiving evidence based clinical management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance to therapy and follow-up rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean Percent Change From Baseline in Lumbar Spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Learning needs (informational needs and educational preferences)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of microcirculatory impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite clinico-biological evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-KLH Antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IJV to CA distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IJV to CA overlap ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Panic Disorder Severity Scale (PDSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of CME
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of VOD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in mucosa health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to neoadjuvant treatment - MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to neoadjuvant treatment - PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to neoadjuvant treatment - Histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to neoadjuvant treatment - Radiomics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HHV-6 biological reactivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change of ultrasound doppler indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in nutritional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 30% reduction in abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Score of 4 or 5 on the SGA scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maternal genetic compatibility profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of diagnosis of hypertensive emergency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes